The field of psychedelic-assisted psychotherapy has been growing rapidly in recent years with decriminalization efforts moving forward on local, state, and federal levels. A multitude of clinical research trials is showing promising results of therapies utilizing MDMA, psilocybin, and ketamine as well as other medicines in the treatment of trauma, depression, addiction, end-of-life, and other mental health conditions.
MDMA is currently in phase three of clinical trial research studies for the treatment of trauma in the United States, Canada, and Israel.
Join clinician and CIIS professor Gisele Fernandes-Osterhold for a conversation with MAPS clinician-researcher Keren Tzarfaty on the benefits and therapeutic applications of MDMA assisted psychotherapy. In this conversation, Keren and Gisele go deep into the nature of the psychedelic experience, the principles that guides the therapeutic work, and the new paradigm this study offers to treatment of PTSD and to psychotherapy in general.
This event is one in a three-part series of conversations exploring the rapidly growing field of psychedelic-assisted psychotherapy.
Learn more about the Series:
Follow us on Facebook, Instagram, and Twitter @ciispubprograms
Donate to CIIS: